Social anxiety disorder

Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe

Retrieved on: 
Wednesday, October 11, 2023
SL, Autoimmunity, Government, Medicine, Headache, DSM-IV codes, CD40L, Research, Risk, Infection, COVID-19, Binge eating disorder, Smallpox, Central nervous system, Upsher-Smith Laboratories, Fibromyalgia, Hydrogen chloride, Annual report, Prader–Willi syndrome, PPAR, Pain, Obesity, Sumatriptan, Breakthrough therapy, Neurology, Cancer, CEST, FDA, Long, Migraine, CNS, MDD, Security (finance), Disease, Congress, Therapy, Failure, Long COVID, Gustav Neuring, Science, Social anxiety disorder, Orphan drug, Psychiatry, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

A copy of the Company’s presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference.

Key Points: 
  • A copy of the Company’s presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference.
  • Additional meeting information can be found on the World Vaccine Congress website here .
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.
  • TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases.

Vistagen Announces Pricing of $100 Million Underwritten Offering

Retrieved on: 
Monday, October 2, 2023
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Exercise, Attention, Montgomery Street, Central nervous system, Depression, William Blair & Company, Anxiety, Telephone, Jefferies, SAD, File hosting service, Research, Sale, Suite, Prospectus, Jefferies Group, PALISADE, Social anxiety disorder, Madison Avenue, Security (finance), Therapy, Stifel, L.L.C, Citadel, Incorporated

Each share of common stock or pre-funded warrant will be sold with an accompanying T1 Warrant and T2 Warrant.

Key Points: 
  • Each share of common stock or pre-funded warrant will be sold with an accompanying T1 Warrant and T2 Warrant.
  • The total gross proceeds to Vistagen from this offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Vistagen and excluding any potential future proceeds of up to $50 million from the exercise of the T1 Warrants and up to $100 million from the exercise of the T2 Warrants.
  • All of the shares of common stock, pre-funded warrants, T1 Warrants, and T2 Warrants to be sold in the offering are being sold by Vistagen.
  • The offering is expected to close on October 4, 2023, subject to the satisfaction of customary closing conditions.

Tonix Pharmaceuticals Announces Proposed Public Offering

Retrieved on: 
Thursday, September 28, 2023
Long COVID, Prader–Willi syndrome, Sumatriptan, Failure, Binge eating disorder, Telephone, Drug Master File, PPAR, Upsher-Smith Laboratories, Autoimmunity, Pain, Acquisition, Social anxiety disorder, Madison Avenue, Migraine, Psychiatry, Headache, Therapy, Capital market, SL, Research, Infection, Risk, Orphan drug, Security (finance), FDA, Long, COVID-19, Cancer, Smallpox, Disease, Government, Breakthrough therapy, Hydrogen chloride, MDD, Annual report, Gustav Neuring, Neurology, Form, CD40L, Obesity, Central nervous system, CNS, Sale, Prospectus, S-3, DSM-IV codes, Nature, Fibromyalgia, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering.

Key Points: 
  • CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced that it intends to offer and sell shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering.
  • All of the securities to be sold in the offering are to be offered by Tonix.
  • The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the public offering, the timing and size of the public offering, the intended use of proceeds from the public offering and other statement that are predictive in nature.

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

Retrieved on: 
Thursday, September 28, 2023
ISI, Central nervous system, University, BNC210, Week, SDS, Sleep, Liver, EST, University of California, San Diego Performance-Based Skills Assessment, CNS, MADRS, Public health, Patient, Data, Grammatical mood, Psychiatry, Insomnia, Social anxiety disorder, Nausea, United Kingdom, DSM-5, FDA, Headache, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Fatigue, Medical imaging, Pharmaceutical industry, Bionomics, PTSD

Company plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the registrational path for BNC210 in PTSD.

Key Points: 
  • Company plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the registrational path for BNC210 in PTSD.
  • “We are excited about the results of the ATTUNE trial that delivered a positive dataset with treatment effects considerably higher than currently approved therapies.
  • Despite the clinical heterogeneity of PTSD, the results of ATTUNE demonstrated broad benefits with BNC210 across a number of symptoms.
  • The company will discuss the topline ATTUNE study results on the webcast today at 8:00am EST and is planning to advance BNC210 for the treatment of PTSD into registrational studies.

Tonix Pharmaceuticals Announces Poster Presentation Involving TNX-1700 in Preclinical Colorectal Cancer Models at the Seventh International Cancer Immunotherapy Conference 2023

Retrieved on: 
Thursday, September 14, 2023
Long COVID, Psychiatry, Prader–Willi syndrome, Headache, Central nervous system, Sumatriptan, Obesity, Failure, Therapy, Binge eating disorder, COVID-19, Infection, Cancer, Smallpox, PPAR, SL, Disease, Research, Risk, Upsher-Smith Laboratories, CNS, Autoimmunity, Government, Pain, Breakthrough therapy, Hydrogen chloride, Orphan drug, MDD, DSM-IV codes, Annual report, Gustav Neuring, Neurology, Social anxiety disorder, Fibromyalgia, Security (finance), FDA, Migraine, CD40L, Long, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults.

Key Points: 
  • Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults.
  • Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates.
  • Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.
  • Enrollment in a Phase 2 proof-of-concept study has been completed, and topline results were reported in the third quarter of 2023.

Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210

Retrieved on: 
Wednesday, August 23, 2023
Clinician Administered PTSD Scale, ISI, Central nervous system, Depression, BNC210, Official List, FOR, Montgomery–Åsberg Depression Rating Scale, Anxiety, SDS, Sleep, BNO, SAD, Australian Securities Exchange, DSM-IV codes, Hamilton Anxiety Rating Scale, Phase 3, Patient, Insomnia, Social anxiety disorder, United Kingdom, PGI, CGI, DSM-5, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Bionomics, PTSD

“I would like to thank study participants, their families, our clinical site investigators and their staff and our clinical team for their contributions towards achieving completion of the ATTUNE study.

Key Points: 
  • “I would like to thank study participants, their families, our clinical site investigators and their staff and our clinical team for their contributions towards achieving completion of the ATTUNE study.
  • The EoPh2 meeting to discuss advancing BNC210 into Phase 3 development as an acute treatment for SAD has been scheduled for mid-September 2023.
  • Additionally, Bionomics is scheduled to delist from the Official List of the Australian Securities Exchange on 28 August 2023.
  • The Company will remain an Australian incorporated company and will maintain its listing of ADSs on Nasdaq under the trading symbol ‘BNOX’.

Tonix Pharmaceuticals to Present at the August Virtual Investor Summit

Retrieved on: 
Thursday, August 17, 2023
Long COVID, Psychiatry, Prader–Willi syndrome, Headache, Central nervous system, Sumatriptan, Obesity, Failure, Therapy, IR, Binge eating disorder, COVID-19, Infection, Cancer, Smallpox, PPAR, SL, Disease, Research, Risk, Upsher-Smith Laboratories, CNS, Autoimmunity, Government, Pain, Breakthrough therapy, Hydrogen chloride, Orphan drug, MDD, DSM-IV codes, Annual report, Neurology, Social anxiety disorder, Fibromyalgia, Security (finance), FDA, Migraine, CD40L, Long, Pharmaceutical industry, CD154, Tonix Pharmaceuticals

CHATHAM, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals, will present at the August 2023 Virtual Investor Summit on Thursday, August 24, 2023, at 10:00 a.m.

Key Points: 
  • CHATHAM, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Gregory Sullivan, M.D., Chief Medical Officer of Tonix Pharmaceuticals, will present at the August 2023 Virtual Investor Summit on Thursday, August 24, 2023, at 10:00 a.m.
  • Investors interested in arranging a meeting with the Company’s management during the conference should contact the Investor Summit conference coordinator.
  • A webcast of the presentation can be found here and will be available under the IR Events tab of the Tonix website at www.tonixpharma.com .
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.

Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results

Retrieved on: 
Thursday, August 10, 2023
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Neuron, Hot, Optimism, Central nervous system, Depression, Nasal cavity, Anxiety, Aes, New Drug Application, Food and Drug Administration, Calendar, Clinical Global Impression, NDA, Woman, Subjective units of distress scale, SAD, Liebowitz social anxiety scale, Multimedia, Brain, CNS, Trial of the century, Visit, PALISADE, MDD, Patient, LSAS, Menopause, Social anxiety disorder, FDA, Fasedienol, Safety, Pharmaceutical industry, Nursing, Medical imaging, Dietary supplement, SUDS

Phase 3 study of an investigational therapy for social anxiety disorder in over 15 years,” said Shawn Singh, Chief Executive Officer of Vistagen.

Key Points: 
  • Phase 3 study of an investigational therapy for social anxiety disorder in over 15 years,” said Shawn Singh, Chief Executive Officer of Vistagen.
  • Positive Phase 3 PALISADE-2 study of fasedienol yields statistically significant top-line results for the acute treatment of anxiety in adults with SAD.
  • Based on the positive top-line results of the Phase 3 PALISADE-2 study, we are currently preparing for our Phase 3 PALISADE-3 trial, with potential to initiate the trial during the first half of calendar 2024.
  • Vistagen will host a conference call and live audio webcast this afternoon at 4:30 p.m. Eastern Time to provide a corporate update.

Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder

Retrieved on: 
Monday, August 7, 2023
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Columbia University, Depression, Central nervous system, Liebowitz social anxiety scale, Anxiety, Aes, SAD, Medicine, CNS, New York State Psychiatric Institute, Visit, Patient, LSAS, Anxiety disorder, Social anxiety disorder, PH94B, Social anxiety, Fasedienol, Safety, Pharmaceutical industry, Nursing, Medical imaging, SUDS

The trial met its primary endpoint, with fasedienol demonstrating a statistically significant difference in average SUDS score during a public speaking challenge compared to placebo (p=0.015).

Key Points: 
  • The trial met its primary endpoint, with fasedienol demonstrating a statistically significant difference in average SUDS score during a public speaking challenge compared to placebo (p=0.015).
  • The trial also met its secondary endpoint, demonstrating a statistically significant difference in the proportion of clinician-assessed responders between fasedienol and placebo as measured by the CGI-I scale (p=0.033).
  • Fasedienol was well-tolerated and demonstrated a favorable safety profile consistent with all prior trials.
  • “As a new class of medicines, our pherine nasal spray pipeline holds the potential to transform the treatment landscape across numerous therapeutic areas.

Virtual Reality Therapy Reduces Stress and Anxiety in Patients by 34% in New Study Published in Cell

Retrieved on: 
Wednesday, August 2, 2023
GAD, Male, Music, Anxiety, Prevalence, Mental health, Mindfulness, Mental, VR, Patient, Reality therapy, Virtual reality, Social anxiety disorder, Physical fitness, Generalized anxiety disorder, Senior counsel, Heart rate, Female, Nursing, Pharmaceutical industry, Cell

BOSTON, Aug. 2, 2023 /PRNewswire/ -- XRHealth, the leading healthcare platform in  Spatial computing, announces today that virtual reality therapy reduces stress and anxiety in patients by 34%, which was published in a new study in Cell. XRHealth's VR technology was used for the therapeutic intervention, which resulted in a decrease of stress in 73% of patients, more so in female patients and those in the 18-24 age bracket.

Key Points: 
  • XRHealth's VR Technology Used for Therapeutic Intervention, Resulting in a Decrease in Stress in 73% of Patients'
    BOSTON, Aug. 2, 2023 /PRNewswire/ -- XRHealth, the leading healthcare platform in  Spatial computing, announces today that virtual reality therapy reduces stress and anxiety in patients by 34%, which was published in a new study in Cell .
  • This study demonstrates the efficacy and accessibility of virtual reality treatment so that patients have multiple therapeutic options."
  • The study was performed on 61 participants who received virtual reality therapy solely in the metaverse.
  • The results highlighted that anxiety (GAD) decreased 34% and stress was reduced by 32% after virtual reality therapy.